Williams McKinley D, Smith Leif
Department of Biology, Texas A&M University, College Station, TX 77843, USA.
Antimicrobial Division, Sano Chemicals Inc., Bryan, TX 77808, USA.
Microorganisms. 2025 Feb 28;13(3):555. doi: 10.3390/microorganisms13030555.
This review highlights several basic problems associated with bacterial drug resistance, including the decreasing efficacy of commercially available antimicrobials as well as the related problem of microbiome irregularity and dysbiosis. The article explains that this present situation is addressable through LAB species, such as and , which are well established synthesizers of both broad- and narrow-spectrum antimicrobials. The sheer number of antimicrobials produced by LAB species and the breadth of their biological effects, both in terms of their bacteriostatic/bactericidal abilities and their immunomodulation, make them prime candidates for new probiotics and antibiotics. Given the ease with which several of the molecules can be biochemically engineered and the fact that many of these compounds target evolutionarily constrained target sites, it seems apparent that these compounds and their producing organisms ought to be looked at as the next generation of robust dual action symbiotic drugs.
本综述强调了与细菌耐药性相关的几个基本问题，包括市售抗菌药物疗效的下降以及微生物群不规则和失调的相关问题。文章解释说，目前的这种情况可以通过乳酸菌物种来解决，例如[未提及具体物种名称]，它们是广谱和窄谱抗菌药物的成熟合成者。乳酸菌物种产生的抗菌药物数量众多，其生物学效应的广度，无论是在抑菌/杀菌能力还是免疫调节方面，都使其成为新型益生菌和抗生素的主要候选者。鉴于其中几种分子易于进行生物化学工程改造，而且这些化合物中的许多靶向进化上受限的靶点，很明显这些化合物及其产生菌应被视为下一代强大的双作用共生药物。
